CHICAGO, IL. (May 28, 2010)––There's debate about the best treatment approach for patients with certain stages of non-small cell lung cancer (NSCLC), which accounts for about 80 percent of all lung cancers. Patients with early stages of NSCLC are typically treated with surgery, but those with stage IIIA present more of a challenge because they are such a diverse group. However, research from Fox Chase Cancer Center shows that patient's with stage IIIA NSCLC who receive surgery, lobectomy in particular, have increased overall survival compared to those who received chemoradiation alone––those receiving lobectomy plus chemoradation had survival rates that were higher than previously reported as well.
The research, led by Charu Aggarwal, M.D., M.P.H., Walter Scott, M.D., F.A.C.S., and George Simon, M.D., will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology on Sunday June 6.
Stage IIIA presents challenges because patients classified at that level are such a diverse group. The common denominator is that cancer has spread to lymph nodes on the same side of the chest as the primary tumor, but beyond that, stage IIIA patients may have tumors of any size and may differ in the number and location of affected lymph nodes.
"In the past, patients with advanced stage lung cancer were treated either with surgery alone, chemotherapy alone, or radiation alone," says Aggarwal. "Scientists and clinicians found that adding radiation to chemotherapy improved survival, so concurrent chemotherapy and radiation together became the standard of care." Recent large, Phase III clinical trials showed that patients treated with chemoradiation followed by surgery were more likely to be disease-free than counterparts who received chemoradiation without surgery set the stage for Aggarwal's study.
Looking at data from 249 patients treated at Fox Chase for stage IIIA non-small cell lung cancer from 2000 through 2008, the research team divided patients into three groups based on the treatments they received: chemoradiation only, chemoradiation plus surgical removal of a lung (pneumonectomy), or chemoradiation plus surgical removal of only one lobe of the lung (lobectomy).
Biostatistician Brian Egleston, Ph.D., used a technique called propensity score analysis to balance the three groups in terms of age, gender, smoking status, physical condition, and other variables that could bias the results.
"After we adjusted for all those variables, we saw that patients who received surgery, lobectomy in particular, had increased overall survival compared to those who received chemoradiation alone," says Aggarwal. "We saw overall survival of 40 percent at five years for chemoradiation plus lobectomy, higher than seen with pneumonectomy."
Removing the entire lung, a more extensive procedure that poses a greater risk of post-operative complications, offered no additional survival benefit." This tells us that you don't have to put the patient through pneumonectomy; you might get superior outcomes with a smaller, safer operation," says Aggarwal, who received an ASCO Foundation Merit Award for this research.
Based on the study's results, Aggarwal, Scott and Simon are undertaking a phase I clinical trial of chemoradiation followed by lobectomy in selected stage IIIA non small cell lung cancer patients.
In addition to Aggarwal, Egleston, Scott and Simon, the paper's authors are Linna Li, M.D.; Hossein Borghaei, D.O.; Ranee Mehra, M.D.; Neeta Somaiah, M.D.; Aruna Turaka, M.D.; Abraham Lebenthal, M.D.; and Corey Langer, M.D.
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.fccc.org or call 1-888-FOX CHASE or (1-888-369-2427).
Presentation Title: Role of surgery in patients with Stage IIIA non-small cell lung Cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience.
Presentation Time: Sunday, June 6 from 8:00 a.m. – 12:00 noon
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.